Injected immunotherapy plus pembrolizumab for resistant melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new approach for advanced melanoma that is not responding to standard immunotherapy (like pembrolizumab). It combines a targeted injection directly into the tumor (L19IL2, L19TNF, or both) with pembrolizumab. The goal is to see if this combination can shrink tumors and help the immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma (stage III or IV) that can't be fully removed with surgery.
- Your melanoma got worse while you were on pembrolizumab or a similar immunotherapy.
- You have at least one tumor in the skin, under skin, or in a lymph node that can be injected (at least 5 mm).
- You have no more than 10 tumors spread to lungs, liver, bones, or brain (brain tumors must be stable and not causing symptoms).
- You are 18 or older, can manage daily activities well, and have good kidney and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This Phase 2 trial studies a specific sequence of immune medicines for people with stage 3 or 4 melanoma that has spread or cannot be removed. It’s designed for melanoma that worsened after prior PD-1 treatment, aiming to shrink tumors and control disease.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab (Keytruda) in people with advanced melanoma that cannot be removed by surgery. The goal is to see if this combination helps the immune system fight the cancer better.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
Hear when a new Melanoma Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.